SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 22, 2011 08:16 ET

Stagnant US Market Forces Medical Supply Makers to Focus on International Operations

The Paragon Report Provides Equity Research on Accuray & Radient Pharmaceuticals

NEW YORK, NY--(Marketwire - Sep 22, 2011) - The Paragon Report examines investing opportunities in the Medical Equipment & Supplies industry and provides equity research on Accuray, Inc. (NASDAQ: ARAY) and Radient Pharmaceuticals Corporation (PINKSHEETS: RXPC). Access to the full company reports can be found at:

www.paragonreport.com/ARAY

www.paragonreport.com/RXPC

Profit margins throughout the medical supplies industry are being hurt from several directions. Companies have had to lower device prices to combat the high unemployment rates, while sweeping healthcare reform that came into effect last year has also crimped profits. In addition to margin concerns, the FDA's medical device approval process continues to confuse the industry.

The Institute of Medicine recently recommended that the US government create a new system of approving medical devices because the current system does not guarantee the products are safe. The panel from the Institute for Medicines also said the FDA should abandon a process that allows for medical devices to be approved if the manufacturers prove they are similar to devices that are already on the market.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Medical Equipment & Supplies industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Several medical supply makers are looking to emerging markets as a means to supplement the tepid growth of domestic medical instrument and supply markets.

Accuray is a global leader in the field of radiosurgery and provides a non-surgical treatment option for patients diagnosed with cancer. The Company's leading-edge technologies -- the CyberKnife and TomoTherapy Systems -- are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. Accuray has significant exposure to Asia, with several treatment centers located in China.

Currently Radient Pharmaceuticals offers its FDA-cleared In Vitro Diagnostic (IVD) Onko-SureTest Kit, which is used for the detection and/or monitoring of 14 different types of cancers. Earlier this month the company announced it has filed for patent protection for its proprietary Onko-Sure cancer test in Australia and New Zealand. The company had recently sold and shipped its first order of Onko-Sure test kits to a distributor in Brazil.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer